SYRE — Spyre Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for Spyre Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 93.1 | 55.7 | 339 | 603 | 757 |
| Net Total Receivables | 0.815 | 0.375 | 0 | — | — |
| Prepaid Expenses | |||||
| Total Current Assets | 98.9 | 62.3 | 342 | 608 | 778 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 9.15 | 7.25 | 0 | — | — |
| Other Long Term Assets | |||||
| Total Assets | 110 | 71.1 | 342 | 608 | 778 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 20.1 | 14.7 | 32 | 54.1 | 58.7 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 26 | 20.8 | 73.3 | 90.7 | 62.5 |
| Redeemable Preferred Stock | |||||
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 83.9 | 50.3 | 269 | 518 | 715 |
| Total Liabilities & Shareholders' Equity | 110 | 71.1 | 342 | 608 | 778 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |